Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions

New England Journal of Medicine

Volumn 370, Issue 12, 2014, Pages 1101-1110

  Goede, Valentin ^a,b   Fischer, Kirsten ^a   Busch, Raymonde ^c   Engelke, Anja ^a   Eichhorst, Barbara ^a   Wendtner, Clemens M ^a,d   Chagorova, Tatiana ^h   De La Serna, Javier ^j   Dilhuydy, Marie Sarah ^k   Illmer, Thomas ^e   Opat, Stephen ^l   Owen, Carolyn J ^m   Samoylova, Olga ⁱ   Kreuzer, Karl Anton ^a   Stilgenbauer, Stephan ^g   Doḧner, Hartmut ^g   Langerak, Anton W ⁿ   Ritgen, Matthias ^f   Kneba, Michael ^f   Asikanius, Elina ^o   Humphrey, Kathryn ^p   Wenger, Michael ^q   Hallek, Michael ^a,b   more..

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Klinikum Schwabing   (Germany)

^e City Hospital Kiel ^*

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g UNIVERSITY OF ULM   (Germany)

^h Penza Regional Oncology Health Center   (Russian Federation)

ⁱ NA Semashko Nizhny Novgorod Regional Clinical Hospital   (Russian Federation)

^j HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^k HAUT LÉVÊQUE HOSPITAL   (France)

^l MONASH MEDICAL CENTRE   (Australia)

^m UNIVERSITY OF CALGARY   (Canada)

ⁿ ERASMUS MEDICAL CENTER   (Netherlands)

^o F HOFFMANN LA ROCHE LTD   (Switzerland)

^p ROCHE PRODUCTS LTD   (United Kingdom)

^q GENENTECH INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CREATININE; OBINUTUZUMAB; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE CLEARANCE; CUMULATIVE ILLNESS RATING SCALE; DEATH; DRUG RESPONSE; FEBRILE NEUTROPENIA; HAZARD RATIO; HEALTH STATUS; HEART DISEASE; HUMAN; INFECTION RISK; INFUSION RELATED REACTION; LEUKOPENIA; MAJOR CLINICAL STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEOPLASM; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; COMORBIDITY; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; REMISSION INDUCTION;

EID: 84894552888     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1313984     Document Type: Article

References (40)

1. Marti GE, Faguet G, Bertin P, et al. CD20 and CD5 expression in B-chronic lymphocytic leukemia. Ann N Y Acad Sci 1992;651:480-3.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010: based on November 2012 SEER data submission, posted to the SEER website. April 2013 (http://seer.cancer.gov/csr/1975-2010).
3. Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008;49:49-56. (Pubitemid 351146882)
4. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-7.
5. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885-91. (Pubitemid 43156283)
6. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230-9. (Pubitemid 47069536)
7. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007;25:793-8. (Pubitemid 350002879)
8. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378-84.
9. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-74.
10. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975-80.
11. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53.
12. Hillmen P, Gribben JG, Follows GA, et al. Rituximab plus chlorambucil in patients with CD20-positive B-cell chronic lymphocytic leukemia (CLL): final response analysis of an open-label Phase II study. Blood 2010;116:697. abstract.
13. Foa R, Ciolli S, Di Raimondo F, et al. Rituximab plus chlorambucil as initial treatment for elderly patients with chronic lymphocytic leukemia (CLL): effect of pre-treatment biological characteristics and gene expression patterns on response to treatment. Blood 2011;118:294. abstract.
14. Cartron G, Watier H, Golay J, Solal- Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104:2635-42. (Pubitemid 39434941)
15. Owen C, Stewart DA. Obinutuzumab for the treatment of lymphoproliferative disorders. Expert Opin Biol Ther 2012;12:343-51.
16. Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115:4393-402.
17. Patz M, Isaeva P, Forcob N, et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011;152:295-306.
18. Dalle S, Reslan L, Besseyre de Horts T, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 2011;10:178-85.
19. Alduaij W, Ivanov A, Honeychurch J, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011;117:4519-29.
20. Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther 2013;12:2031-42.
21. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-56. [Erratum, Blood 2008;112:5259.]
22. Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 1995;43:130-7.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
24. Goede V, Fischer K, Busch R, et al. Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in. Leukemia 2013;27:1172-4.
25. Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009;114:3382-91.
26. Morschhauser F, Salles G, Cartron G, et al. Dose selection for phase III studies of the monoclonal anti-CD20 antibody obinutuzumab (GA101) - a rational approach. Haematologica 2011;96:Suppl 2:935. abstract.
27. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6. (Pubitemid 32064784)
28. Kröber A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410-6. (Pubitemid 34864299)
29. Salvi F, Miller MD, Grilli A, et al. A manual of guidelines to score the modified Cumulative Illness Rating Scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc 2008;56:1926-31.
30. Common Terminology Criteria for Adverse Events v4.03 (CTCAE) (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf) .
31. Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007;21:956-64. (Pubitemid 46672072)
32. Ritgen M, Böttcher S, Stilgenbauer S, et al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia 2008;22:1377-86. (Pubitemid 352006082)
33. Böttcher S, Stilgenbauer S, Busch R, et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia 2009;23:2007-17.
34. Woyach JA, Ruppert AS, Rai K, et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol 2013;31:440-7.
35. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616-23.
36. Robak T. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. Future Oncol 2013;9:69-91.
37. Böttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012;30:980-8.
38. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-70. (Pubitemid 32366970)
39. O'Brien S, Wierda WG, Federl S, et al. FCR-3 as frontline therapy for patients with chronic lymphocytic leukemia. Blood 2005;106:2117. abstract.
40. Morschhauser F, Cartron G, Lamy T, et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Blood 2009;114:884. abstract.